Long-term survival of 11 years with multidisciplinary therapy for hepatocellular carcinoma metastasis to the ovary and peritoneum: a case report.
Case report
Hepatocellular carcinoma
Multidisciplinary therapy
Ovary
Peritoneum
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
04
02
2021
accepted:
02
05
2021
pubmed:
13
5
2021
medline:
27
7
2021
entrez:
12
5
2021
Statut:
ppublish
Résumé
We herein report a rare case of HCC metastases to the ovary and peritoneum in a 61-year-old female patient who has achieved 11-year survival with multidisciplinary therapy. The patient was diagnosed with HCC during balloon angioplasty performed for Budd-Chiari syndrome in 1994 and underwent partial hepatectomy twice. Five years after the second hepatectomy, allochronic recurrence of a single nodule detected in S8 was treated by radiofrequency ablation, followed by percutaneous ethanol injection therapy and stereotactic body radiotherapy. However, her α-fetoprotein level rose to 1862 ng/mL within one year and computed tomography revealed a large pelvic tumor suggesting HCC metastasis to the ovary. The subsequent laparotomy revealed one 11-cm left ovarian tumor, one small right ovarian nodule, and numerous peritoneal nodules. Bilateral salpingo-oophorectomy and peritoneal resection of as many nodules as possible were performed. Combination therapy with intravenous 5-fluorouracil plus cisplatin and ramucirumab monotherapy effectively suppressed tumor progression with maintenance of hepatic functional reserve, and she has achieved long-term survival of 11 years, illustrating that multidisciplinary therapy with favorable hepatic functional reserve maintenance can contribute to long-term survival in HCC with extrahepatic spread.
Identifiants
pubmed: 33978943
doi: 10.1007/s12328-021-01434-2
pii: 10.1007/s12328-021-01434-2
pmc: PMC8298212
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1211-1220Informations de copyright
© 2021. The Author(s).
Références
Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117:4475–83.
doi: 10.1002/cncr.25960
Oortman EH, Elliot JP. Hepatocellular carcinoma metastatic to the ovary: a case report. Am J Obstet Gynecol. 1983;146:715–7.
doi: 10.1016/0002-9378(83)91020-7
Yoon SW, Jeong J-S, Kim SY, et al. A Case of needle-tract implantation of hepatocellular carcinoma in the ovary after radiofrequency ablation. Kosin Med J. 2017;32:251.
doi: 10.7180/kmj.2017.32.2.251
Ishizaki M, Kaibori M, Matsui K, et al. A case of advanced hepatocellular carcinoma in which complete response was achieved with multimodality therapy. Gan To Kagaku Ryohols. 2013;40:1678–80.
Kim MJ. A case of metastatic hepatocellular carcinoma of the ovary: an immunohistochemical study and literature review. Korean J Pathol. 2005;39:287–90.
Khunamornpong S, Siriaunkgul S, Chunduan A. Metastatic hepatocellular carcinoma of the ovary. Int J Gynecol Obstet. 1999;64:189–91.
doi: 10.1016/S0020-7292(98)00170-2
Lim TK, Uhm JE, Cheong H-S, et al. A case of hepatocellular carcinoma with ovarian metastasis. Korean J Med. 2006;71:573–6.
Young RH, Gersell DJ, Clement PB, et al. Hepatocellular carcinoma metastatic to the ovary: a report of three cases discovered during life with discussion of the differential diagnosis of hepatoid tumors of the ovary. Hum Pathol. 1992;23:574–80.
doi: 10.1016/0046-8177(92)90136-Q
De Groot ME, Dukel L, Chadha-Ajwani S, et al. Massive solitary metastasis of hepatocellular carcinoma in the ovary two years after liver transplantation. Eur J Obstet Gynecol Reprod Biol. 2000;90:109–11.
doi: 10.1016/S0301-2115(99)00212-2
Lee JM, Park KM, Lee SY, et al. Metastasis of hepatocellular carcinoma to the ovary: a case report and review of the literature. Gut Liver. 2011;5:543–7.
doi: 10.5009/gnl.2011.5.4.543
Cil I, Zirtiloglu A, Velibeyoglu MF, et al. What is the optimal treatment of metastatic hepatocellular carcinoma after complete resection; case presentation of ovarian metastasis—PubMed. J BUON. 2017;22:557–8.
pubmed: 28534387
Stippel DL, Kasper HU, Schleimer K, et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2005;37:2185–7.
doi: 10.1016/j.transproceed.2005.03.013
Böcher WO, Löhr HF, Steegmüller KW, et al. Detection of hepatitis C virus replication in ovarian metastases of a patient with hepatocellular carcinoma. J Hepatol. 1994;21:47–51.
doi: 10.1016/S0168-8278(94)80135-5
Park JH, Han CD, Huh CK, et al. Hepatocellular carcinoma metastatic to the ovary: one case report and review literature. Korean J Obstet Gynecol. 2001;44:1900–4.
Kim TH, Cheung DY, Chung WB, et al. A case of metastatic hepatocellular carcinoma of the ovary. Korean J Gastroenterol. 2004;43:215–8.
pubmed: 15034293
Nakashima T, Okuda K, Kojiro M, et al. Pathology of hepatocellular carcinoma in Japan: 232 consecutive cases autopsied in ten years. Cancer. 1983;51:863–77.
doi: 10.1002/1097-0142(19830301)51:5<863::AID-CNCR2820510520>3.0.CO;2-D
Wang Y, Yang J, Yu M, et al. Ovarian yolk sac tumor in postmenopausal females: a case series and a literature review. Medicine (Baltimore). 2018;97.
Ishikura H, Scully RE. Hepatoid carcinoma of the ovary. A newly described tumor. Cancer. 1987;60:2775–84.
doi: 10.1002/1097-0142(19871201)60:11<2775::AID-CNCR2820601130>3.0.CO;2-S
Pandey M, Truica C. Hepatoid carcinoma of the ovary. J Clin Oncol. 2011;29.
Wang L, Zhong Y, Sun L, et al. Clinical and pathological features of hepatoid carcinoma of the ovary. World J Surg Oncol. 2013;11.
Choi WK, Cho DH, Yim CY, et al. Primary hepatoid carcinoma of the ovary: a case report and review of the literature. Medicine (Baltimore). 2020;99:e20051.
doi: 10.1097/MD.0000000000020051
Jaskolka JD, Asch MR, Kachura JR, et al. Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol. 2005;16:485–91.
doi: 10.1097/01.RVI.0000151141.09597.5F
Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274–83.
doi: 10.1002/hep.23485
Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821–9.
doi: 10.1016/j.jhep.2012.06.014
Sakamoto K, Nakashima K, Migo S, et al. A study of treatment for extrahepatic metastasis after sugical treatment of hepatocellular carcinoma. Jpn J Gastroenterol Surg. 2002;35:116–9.
doi: 10.5833/jjgs.35.116
Nakayama H, Takayama T, Makuuchi M, et al. Resection of peritoneal metastases from hepatocellular carcinoma—PubMed. Hepatogastroenterology. 1999;46:1049–52.
pubmed: 10370665
Lin CC, Liang HP, Lee HS, et al. Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis. J Gastroenterol Hepatol. 2009;24:815–20.
doi: 10.1111/j.1440-1746.2009.05848.x
Takemura N, Hasegawa K, Aoki T, et al. Surgical resection of peritoneal or thoracoabdominal wall implants from hepatocellular carcinoma. Br J Surg. 2014;101:1017–22.
doi: 10.1002/bjs.9489
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.
doi: 10.1056/NEJMoa0708857
Kanayama M, Nagai H, Sumino Y. Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009;64:109–14.
doi: 10.1007/s00280-008-0851-2
Ueshima K, Kudo M, Takita M, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology. 2010;78:148–53.
doi: 10.1159/000315244
Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106:1990–7.
doi: 10.1002/cncr.21832
Furuse J, Okusaka T, Kaneko S, et al. Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. Cancer Sci. 2010;101:2606–11.
doi: 10.1111/j.1349-7006.2010.01730.x
Kudo M, Moriguchi M, Numata K, et al. S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:407–17.
doi: 10.1016/S2468-1253(17)30072-9
Ye L, Liang R, Zhang J, et al. Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy. Ann Transl Med. 2019;7:367–367.
doi: 10.21037/atm.2019.06.01
Xu L, Wu J, Lu W, et al. Application of the albumin-bilirubin grade in predicting the prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis. Transpl Proc. 2019;51:3338–46.
doi: 10.1016/j.transproceed.2019.08.027
Oh IS, Sinn DH, Kang TW, et al. Liver function assessment using albumin-bilirubin grade for patients with very early-stage hepatocellular carcinoma treated with radiofrequency ablation. Dig Dis Sci. 2017;62:3235–42.
doi: 10.1007/s10620-017-4775-8
Gui B, Weiner AA, Nosher J, et al. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated with Radioembolization. Am J Clin Oncol Cancer Clin Trials. 2018;41:861–6.
Su T-SS, Yang H-MM, Zhou Y, et al. Albumin—Bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy. Radiat Oncol. 2019;14:50.
Kuo YH, Wang JH, Hung CH, et al. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017;32:1975–81.
doi: 10.1111/jgh.13783
Hiraoka A, Kumada T, Atsukawa M, et al. Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma. Oncology. 2019;97:277–85.
doi: 10.1159/000501281
Ueshima K, Nishida N, Hagiwara S, et al. Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study. Cancers (Basel). 2019;11.
Hatanaka T, Naganuma A, Shibasaki M, et al. The role of the albumin-bilirubin score for predicting the outcomes in Japanese patients with advanced hepatocellular carcinoma treated with ramucirumab: a real-world study. Oncology. 2020.
Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282–96.
doi: 10.1016/S1470-2045(18)30937-9
Wada Y, Takami Y, Ryu T, et al. A case of advanced hepatocellular carcinoma with partial response after continuous ramucirumab treatment beyond radiological progression. Case Rep Oncol. 2020;13:379–84.
doi: 10.1159/000506331
Kudo M, Galle PR, Llovet JM, et al. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int. 2020;40:2008–20.
doi: 10.1111/liv.14462
Wang D, Yang X, Lin J, et al. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. Therap Adv Gastroenterol. 2020;13.